Table 1.

Clinical and Molecular Features of Primary ESFT Biopsies

		BMI-1 Score
		BMI-1-low		BMI-1-high
	All Patients	Negative	1+	2+	3+	p-value*
Total Number	130	18	6	33	73
(%)	(100)	(13.8)	(4.6)	(25.4)	(56.2)
Median age, years (range)	13 (0, 47)	13 (5, 47)	15 (6, 31)	15 (0, 30)	13 (0, 46)	0.76(1)
Gender
Male (%)	84 (65)	13	1	25	45	0.04(2); 0.49(3)
Female (%)	46 (35)	5	5	8	28
Stage
Localized (%)	99 (85)	11	4	22	62	0.43(2)
Metastatic (%)	18 (15)	4	1	4	9
Unknown	13	3	1	7	2
Region
Pelvis (%)	20 (15)	4	1	3	12	0.56(2)
Non-Pelvis (%)	110 (85)	14	5	30	61
Tissue of Origin
Bone	75	12	3	19	41	0.72(2)
Soft Tissue	50	5	2	11	32
Unknown	5	1	1	3	0
Chemotherapy status
Pre-Chemotherapy	99	13	3	24	59	0.49(2)
Post-chemotherapy	15	3	1	4	7
Unknown	16	2	2	5	7
Translocation status
EWS-ETS Fusion +	70	5	5	18	42	0.13(2)
No fusion detected	5	2	0	0	3
Unknown	55	11	1	15	28
p16 genomic status known (N=24)
Wild type	22	3	2	7	10	0.52(2)
Deleted	2	0	1	0	1
p53 mutation status known (N=24)
Wild type	16	3	1	5	7	0.55(2)
Mutant	8	0	2	2	4

^*p-value from analysis of variance¹, 4×2 Fisher’s exact test (unknowns excluded) ², 2×2 Fisher’s exact test³